Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Undergoing Neoadjuvant Immunotherapy With Chemotherapy

NCT07862751 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT07862751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Undergoing Neoadjuvant Immunotherapy With Chemotherapy
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, triple-negative breast carcinoma